the approval of aripiprazole lauroxil from the food and drug administration in 2015 was solely for the treatment of schizophrenia in adults. the ability to supplement aripiprazole lauroxil with oral supplements of aripiprazole allows for dosing flexibility, which is important for the treatment of schizophrenia, as symptoms and intensity of the disease vary greatly from patient to patient. additionally, as in concurrence with its sister drug aripiprazole, aripiprazole lauroxil is similar in effect of typical antipsychotic drugs. in the sister drug aripiprazole, side effects for patients were less frequently extrapyramidal than most antipsychotic drugs.